{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:38:07Z","timestamp":1792654687662,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001563","name":"Otago Medical Research Foundation","doi-asserted-by":"publisher","award":["LA394"],"award-info":[{"award-number":["LA394"]}],"id":[{"id":"10.13039\/501100001563","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejpb.2023.12.010","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T02:27:56Z","timestamp":1702952876000},"page":"114170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections"],"prefix":"10.1016","volume":"195","author":[{"given":"Tushar","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah Bow","family":"Yue Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-5601","authenticated-orcid":false,"given":"Miguel E.","family":"Qui\u00f1ones-Mateu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5750-7505","authenticated-orcid":false,"given":"Daniel","family":"Pletzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0823-8147","authenticated-orcid":false,"given":"Shyamal C.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2019","key":"10.1016\/j.ejpb.2023.12.010_b0005","first-page":"598","article-title":"Contemporary concise review 2018: respiratory infections and tuberculosis","volume":"24","author":"Hui","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.ejpb.2023.12.010_b0010","article-title":"Inhaled dry powder formulation of tamibarotene, a broad-spectrum antiviral against respiratory viruses including SARS-COV-2 and influenza virus","volume":"4","author":"Liao","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejpb.2023.12.010_b0015","unstructured":"World Health Organization, The top 10 causes of death, 2020, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death (accessed 10 August 2023)."},{"key":"10.1016\/j.ejpb.2023.12.010_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261720","article-title":"Inhaled ciprofloxacin-loaded poly(2-ethyl-2-oxazoline) nanoparticles from dry powder inhaler formulation for the potential treatment of lower respiratory tract infections","volume":"16","author":"Sabuj","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.12.010_b0025","article-title":"Appropriateness of antibiotic treatment of acute respiratory tract infections in Tunisian primary care and emergency departments: a multicenter cross-sectional study","volume":"23","author":"Ali","year":"2022","journal-title":"BMC Prim. Care"},{"key":"10.1016\/j.ejpb.2023.12.010_b0030","article-title":"Antibiotic resistance: the challenges and some emerging strategies for tackling a global menace","volume":"36","author":"Nwobodo","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.ejpb.2023.12.010_b0035","unstructured":"World Health Organization, WHO publishes list of bacteria for which new antibiotics are urgently needed, 2017, https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed 10 August 2023)."},{"key":"10.1016\/j.ejpb.2023.12.010_b0040","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","article-title":"Drug combination therapy for emerging viral diseases","volume":"26","author":"Shyr","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2023.12.010_b0045","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug repurposing approach to fight COVID-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejpb.2023.12.010_b0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/IDR.S287792","article-title":"Encouraging the development of new antibiotics: are financial incentives the right way forward? A systematic review and case study","volume":"14","author":"Dutescu","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.ejpb.2023.12.010_b0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2023.12.010_b0060","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1007\/s11033-014-3417-x","article-title":"Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways","volume":"41","author":"Azad","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejpb.2023.12.010_b0065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/ijms24021610","article-title":"Antibacterial activity of ebselen","volume":"24","author":"Maslanka","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.12.010_b0070","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0140-6736(17)31791-9","article-title":"Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"390","author":"Kil","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2023.12.010_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26144230","article-title":"Ebselen and analogues: pharmacological properties and synthetic strategies for their preparation","volume":"26","author":"Santi","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2023.12.010_b0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.freeradbiomed.2020.06.032","article-title":"Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections","volume":"156","author":"Sies","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejpb.2023.12.010_b0085","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3389\/fmicb.2019.03016","article-title":"Topical therapeutic efficacy of ebselen against multidrug-resistant staphylococcus aureus LT-1 targeting thioredoxin reductase","volume":"10","author":"Dong","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejpb.2023.12.010_b0090","first-page":"1265","article-title":"Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis","volume":"2016","author":"Gustafsson","year":"1860","journal-title":"BBA"},{"key":"10.1016\/j.ejpb.2023.12.010_b0095","doi-asserted-by":"crossref","DOI":"10.1038\/srep11596","article-title":"Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections","volume":"5","author":"Thangamani","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.12.010_b0100","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1096\/fj.12-223305","article-title":"Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione","volume":"27","author":"Lu","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.ejpb.2023.12.010_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133877","article-title":"Repurposing clinical molecule ebselen to combat drug resistant pathogens","volume":"10","author":"Thangamani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.12.010_b0110","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.sjbs.2020.10.040","article-title":"Evaluating the effect of antibiotics sub-inhibitory dose on Pseudomonas aeruginosaquorum sensing dependent virulence and its phenotypes","volume":"28","author":"Aleanizy","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.ejpb.2023.12.010_b0115","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1365-2672.2009.04529.x","article-title":"The effect of subminimal inhibitory concentrations of antibiotics on virulence factors expressed by Staphylococcus aureus biofilms","volume":"108","author":"Haddadin","year":"2010","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.ejpb.2023.12.010_b0120","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1080\/03639045.2019.1609494","article-title":"Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis","volume":"45","author":"Momin","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.010_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120345","article-title":"Studies on the safety and the tissue distribution of inhaled high-dose amorphous and crystalline rifampicin in a rat model","volume":"597","author":"Khadka","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.010_b0130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.drudis.2021.09.005","article-title":"Developing inhaled drugs for respiratory diseases: a medicinal chemistry perspective","volume":"27","author":"Pasqua","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2023.12.010_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122042","article-title":"Inhaled therapy for COVID-19: considerations of drugs, formulations and devices","volume":"624","author":"Saha","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.010_b0140","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/00006454-199808001-00002","article-title":"Microbiology of bacterial respiratory infections","volume":"17","author":"Cappelletty","year":"1998","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.ejpb.2023.12.010_b0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrmicro.2017.14","article-title":"The microbiota of the respiratory tract: gatekeeper to respiratory health","volume":"15","author":"Man","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejpb.2023.12.010_b0150","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0021-8502(86)90035-2","article-title":"Deposition of particles in the human respiratory tract in the size range 0.005\u201315 \u03bcm","volume":"17","author":"Heyder","year":"1986","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejpb.2023.12.010_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121657","article-title":"Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system","volume":"618","author":"Alhajj","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.010_b0160","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40005-017-0359-z","article-title":"Dry powder inhaler for pulmonary drug delivery: human respiratory system, approved products and therapeutic equivalence guideline","volume":"48","author":"Lee","year":"2017","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ejpb.2023.12.010_b0165","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ijpharm.2018.08.061","article-title":"High dose dry powder inhalers to overcome the challenges of tuberculosis treatment","volume":"550","author":"Momin","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.ejpb.2023.12.010_b0170","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/17425247.2022.2089111","article-title":"An expert opinion on respiratory delivery of high dose powders for lung infections","volume":"19","author":"Adhikari","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2023.12.010_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12080715","article-title":"Co-amorphization of kanamycin with amino acids improves aerosolization","volume":"12","author":"Adhikari","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.12.010_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121799","article-title":"Amino acids improve aerosolization and chemical stability of potential inhalable amorphous spray-dried ceftazidime for pseudomonas aeruginosa lung infection","volume":"621","author":"Adhikari","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.010_b0185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpharm.2017.06.004","article-title":"Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis","volume":"528","author":"Momin","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.010_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071432","article-title":"Manipulation of spray-drying conditions to develop an inhalable ivermectin dry powder","volume":"14","author":"Saha","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.ejpb.2023.12.010_b0195","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/10717544.2014.883113","article-title":"Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance","volume":"21","author":"Yang","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2023.12.010_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13010031","article-title":"Dry powder for pulmonary delivery: a comprehensive review","volume":"13","author":"Chaurasiya","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.12.010_b0205","article-title":"Optimization of methionine in inhalable high-dose spray-dried amorphous composite particles using response surface method, infrared and low frequency Raman spectroscopy","volume":"614","author":"Adhikari","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.010_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15092229","article-title":"Spray-dried inhalable microparticles combining remdesivir and ebselen against SARS-CoV-2 infection","volume":"15","author":"Saha","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.12.010_b0215","doi-asserted-by":"crossref","first-page":"41846","DOI":"10.1039\/D0RA07203F","article-title":"Advanced design and development of nanoparticle\/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols","volume":"10","author":"Muralidharan","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2023.12.010_b0220","first-page":"275","volume":"8","author":"Meenach","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.12.010_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123411","article-title":"Inhalable dry powder containing remdesivir and disulfiram: preparation and in vitro characterization","volume":"645","author":"Saha","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.010_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118689","article-title":"Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis","volume":"570","author":"Rangnekar","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.010_b0235","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/089426803769017659","article-title":"Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: design","volume":"16","author":"Marple","year":"2003","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.ejpb.2023.12.010_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11100502","article-title":"Inhalable dry powder of bedaquiline for pulmonary tuberculosis: in vitro physicochemical characterization, antimicrobial activity and safety studies","volume":"11","author":"Momin","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.12.010_b0245","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1021\/acs.molpharmaceut.9b00496","article-title":"Effect of particle formation process on characteristics and aerosol performance of respirable protein powders","volume":"16","author":"Brunaugh","year":"2019","journal-title":"Mol Phar."},{"key":"10.1016\/j.ejpb.2023.12.010_b0250","unstructured":"Centers for Disease Control and Prevention (CDC), Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections--Los Angeles County, California, 2002\u20132003. MMWR Morb. Mortal Wkly. Rep. 52 (2003) 88."},{"key":"10.1016\/j.ejpb.2023.12.010_b0255","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(96)05169-0","article-title":"Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic","volume":"348","author":"Cheng","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2023.12.010_b0260","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01842-15","article-title":"Kisameet clay exhibits potent antibacterial activity against the ESKAPE pathogens","volume":"7","author":"Behroozian","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.ejpb.2023.12.010_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007084","article-title":"Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens","volume":"14","author":"Pletzer","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejpb.2023.12.010_b0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nprot.2007.521","article-title":"Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances","volume":"3","author":"Wiegand","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejpb.2023.12.010_b0275","unstructured":"Clinical and laboratory standards institute susceptibility testing. CLSI supplement M100, 33rd Edition, 2023."},{"key":"10.1016\/j.ejpb.2023.12.010_b0280","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/s41596-021-00515-3","article-title":"Microtiter plate assays to assess antibiofilm activity against bacteria","volume":"16","author":"Haney","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejpb.2023.12.010_b0285","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijpharm.2013.01.003","article-title":"Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance","volume":"443","author":"Son","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.010_b0290","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12100976","article-title":"Simple method to measure the aerodynamic size distribution of porous particles generated on lyophilizate for dry powder inhalation","volume":"12","author":"Miyamoto","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.12.010_b0295","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.drudis.2021.04.009","article-title":"Leucine as an excipient in spray dried powder for inhalation","volume":"26","author":"Alhajj","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2023.12.010_b0300","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-020-02890-0","article-title":"Solvent-assisted secondary drying of spray-dried polymers","volume":"37","author":"Shepard","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.12.010_b0305","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425247.5.8.909","article-title":"What is the role of particle morphology in pharmaceutical powder aerosols?","volume":"5","author":"Chan","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2023.12.010_b0310","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/07373930701536718","article-title":"Crystallization of amorphous components in spray-dried powders","volume":"25","author":"Chiou","year":"2007","journal-title":"Drying Technol."},{"key":"10.1016\/j.ejpb.2023.12.010_b0315","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.addr.2020.05.003","article-title":"Post-inhalation cough with therapeutic aerosols: formulation considerations","volume":"165","author":"Sahakijpijarn","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.12.010_b0320","doi-asserted-by":"crossref","first-page":"178","DOI":"10.14356\/kona.2002020","article-title":"Physical properties of supercritically-processed and micronised powders for respiratory drug delivery","volume":"20","author":"Shekunov","year":"2002","journal-title":"KONA"},{"key":"10.1016\/j.ejpb.2023.12.010_b0325","series-title":"Drug Discovery Targeting Drug-Resistant Bacteria","first-page":"105","article-title":"Repurposing nonantibiotic drugs as antibacterials","author":"Thakare","year":"2020"},{"key":"10.1016\/j.ejpb.2023.12.010_b0330","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.969326","article-title":"Biofilm aggregates and the host airway-microbial interface","volume":"12","author":"Hall-Stoodley","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejpb.2023.12.010_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.877995","article-title":"Klebsiella pneumoniae biofilms and their role in disease pathogenesis","volume":"12","author":"Guerra","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.ejpb.2023.12.010_b0340","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2014.10.022","article-title":"Inhaled formulations and pulmonary drug delivery systems for respiratory infections","volume":"85","author":"Zhou","year":"2015","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112300334X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112300334X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:40:39Z","timestamp":1762332039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112300334X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":68,"alternative-id":["S093964112300334X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.010","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114170"}}